1) Arakawa R, Ito H, Takano A, et al:Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology(Berl) 197:229-235, 2007
2) Bressan RA, Erlandsson K, Spencer EP, et al:Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology(Berl) 175:367-373, 2004
3) Farde L, Nordstrom AL, Wiesel FA, et al:Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544, 1992
4) Hugenholtz GW, Heerdink ER, Stolker JJ, et al:Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia:Comparison with officially recommended doses. J Clin Psychiatry 67:897-903, 2006
5) Kane J, Canas F, Kramer M, et al:Treatment of schizophrenia with paliperidone extended-release tablets:A 6-week placebo-controlled trial. Schizophr Res 90:147-161, 2007
6) Kapur S, Zipursky R, Jones C, et al:Relationship between dopamine D2 occupancy, clinical response, and side effects:A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520, 2000
7) Kapur S, Zipursky RB, Remington G, et al:5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia:A PET investigation. Am J Psychiatry 155:921-928, 1998
8) Lappin G, Garner RC:Big physics, small doses:The use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2:233-240, 2003
9) Mamo D, Graff A, Mizrahi R, et al:Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia:a triple tracer PET study. Am J Psychiatry 164:1411-1417, 2007
10) Nordstrom AL, Farde L:Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 18:305-310, 1998
11) Nordstrom AL, Farde L, Wiesel FA, et al:Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects:A double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235, 1993
12) Nyberg S, Eriksson B, Oxenstierna G, et al:Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869-875, 1999
13) Pilowsky LS, Mulligan RS, Acton PD, et al:Limbic selectivity of clozapine. Lancet 350:490-491, 1997
14) Seeman P, Lee T:Antipsychotic drugs:Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219, 1975
15) 杉山雄一,栗原千絵子,馬屋原宏,他:マイクロドーズ臨床試験の実施基盤―指針作成への提言.臨床評価 33:649-677,2006
16) 杉山雄一,馬屋原宏,池田敏彦,他:マイクロドーズ臨床試験の実施基盤・第3報―早期探索的臨床試験の実施に関するガイダンス(案).臨床評価 34:571-594,2007
17) 杉山雄一,栗原千絵子 編著:マイクロドース臨床試験 理論と実践―新たな創薬開発ツールの活用に向けて.じほう,2007
18) Takano A, Suhara T, Ikoma Y, et al:Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 7:19-26, 2004
19) Takano A, Suhara T, Yasuno F, et al:The antipsychotic sultopride is overdosed--a PET study of drug-induced receptor occupancy in comparison with sulpiride. Int J Neuropsychopharmacol 9:539-545, 2006
20) Talvik M, Nordstrom AL, Nyberg S, et al:No support for regional selectivity in clozapine-treated patients:A PET study with[11C]raclopride and[11C]FLB 457. Am J Psychiatry 158:926-930, 2001
21) Yasuno F, Suhara T, Okubo Y, et al:Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology(Berl) 154:112-114, 2001
22) Yokoi F, Grunder G, Biziere K, et al:Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole(OPC 14597):A study using positron emission tomography and[11C]raclopride. Neuropsychopharmacology 27:248-259, 2002